NHAS
Novo Holdings A/S Portfolio holdings
AUM
$1.42B
This Quarter Return
+6.62%
1 Year Return
+12.08%
3 Year Return
+99.82%
5 Year Return
+98.46%
10 Year Return
+612.59%
AUM
$2.01B
AUM Growth
+$2.01B
(+30%)
Cap. Flow
+$487M
Cap. Flow
% of AUM
24.2%
Top 10 Holdings %
Top 10 Hldgs %
74.76%
Holding
43
New
8
Increased
5
Reduced
12
Closed
1
Top Buys
| 1 |
Harmony Biosciences
HRMY
|
$127M |
| 2 |
Apple
AAPL
|
$101M |
| 3 |
Nkarta
NKTX
|
$84M |
| 4 |
CTLT
CATALENT, INC.
CTLT
|
$68.6M |
| 5 |
INZY
Inozyme Pharma
INZY
|
$67.5M |
Top Sells
| 1 |
Vaxcyte
PCVX
|
$11.4M |
| 2 |
SI-BONE Inc
SIBN
|
$6.91M |
| 3 |
Corvus Pharmaceuticals
CRVS
|
$6.17M |
| 4 |
Inspire Medical Systems
INSP
|
$2.57M |
| 5 |
ETTX
Entasis Therapeutics Holdings Inc.
ETTX
|
$2.1M |
Sector Composition
| 1 | Healthcare | 54.36% |
| 2 | Technology | 7.2% |
| 3 | Communication Services | 5.36% |
| 4 | Financials | 5.04% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1
Vanguard Total Stock Market ETF
VTI
$526B
| $523M | 25.96% | 3,070,400 | – | – |
|
|
2
Apple
AAPL
$3.45T
| $145M | 7.2% | 1,252,104 +873,878 | +231% | +$101M |
|
|
CTLT
3
DELISTED
CATALENT, INC.
CTLT
| $139M | 6.91% | 1,626,000 +801,261 | +97% | +$68.6M |
|
|
4
Harmony Biosciences
HRMY
$2.12B
| $127M | 6.32% | +3,754,973 | New | +$127M |
|
5
Cable One
CABO
$909M
| $108M | 5.36% | 57,291 | – | – |
|
6
Inogen
INGN
$216M
| $103M | 5.11% | 3,549,320 -1 | -0% | -$29 |
|
7
Medtronic
MDT
$119B
| $103M | 5.1% | 988,136 | – | – |
|
8
Brookfield
BN
$98.3B
| $102M | 5.04% | 3,070,957 | – | – |
|
|
9
Nkarta
NKTX
$151M
| $84M | 4.17% | +2,793,864 | New | +$84M |
|
|
MORF
10
DELISTED
Morphic Holding, Inc. Common Stock
MORF
| $72.3M | 3.59% | 2,645,446 | – | – |
|
|
INZY
11
DELISTED
Inozyme Pharma
INZY
| $67.5M | 3.35% | +2,569,379 | New | +$67.5M |
|
12
Mirum Pharmaceuticals
MIRM
$3.71B
| $47.1M | 2.34% | 2,445,147 | – | – |
|
13
Amicus Therapeutics
FOLD
$2.34B
| $32.8M | 1.63% | 2,320,026 | – | – |
|
|
14
Vaxcyte
PCVX
$4B
| $32.2M | 1.6% | 651,255 -230,643 | -26% | -$11.4M |
|
|
GRTX
15
DELISTED
Galera Therapeutics, Inc. Common Stock
GRTX
| $30.8M | 1.53% | 3,409,021 | – | – |
|
|
CMPI
16
DELISTED
Checkmate Pharmaceuticals, Inc. Common Stock
CMPI
| $25M | 1.24% | +2,170,100 | New | +$25M |
|
|
SPNE
17
DELISTED
SeaSpine Holdings Corporation Common Stock
SPNE
| $24M | 1.19% | 1,677,492 -112,939 | -6% | -$1.62M |
|
|
BPMC
18
DELISTED
Blueprint Medicines
BPMC
| $21.8M | 1.08% | 234,979 -21,788 | -8% | -$2.02M |
|
|
19
SI-BONE Inc
SIBN
$719M
| $16.6M | 0.82% | 698,504 -291,323 | -29% | -$6.91M |
|
20
Protagonist Therapeutics
PTGX
$3.67B
| $15.5M | 0.77% | 794,369 -29,800 | -4% | -$583K |
|
21
Milestone Pharmaceuticals
MIST
$156M
| $15.2M | 0.76% | 2,080,585 | – | – |
|
|
FLXN
22
DELISTED
Flexion Therapeutics, Inc.
FLXN
| $14.6M | 0.73% | 1,403,370 | – | – |
|
23
Insmed
INSM
$28.8B
| $13.8M | 0.69% | 430,107 | – | – |
|
24
Iovance Biotherapeutics
IOVA
$807M
| $12.7M | 0.63% | +384,938 | New | +$12.7M |
|
|
CNST
25
DELISTED
Constellation Pharmaceuticals, Inc.
CNST
| $11.7M | 0.58% | 578,134 +141,003 | +32% | +$2.86M |
|